In Re: National Prescription Opiate Litigation

Track this case

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. February 03, 2023

    Opioids Ravaged Ga. Family, Jury Told In Distributor Case

    A Georgia fire captain took the stand Friday as the first plaintiff to testify in a private opioid trial against major drug distributors, telling jurors the drugs exacted a heavy toll on his relatives and their relationships.

  2. January 31, 2023

    DEA Faulted Controls At Opioid Distributors, Ga. Jury Hears

    A Georgia jury weighing claims that major drug distributors fueled addiction heard Tuesday from a former U.S. Drug Enforcement Administration agent who testified that the regulator repeatedly investigated Cardinal Health and McKesson warehouses nationwide and found the distributors weren't properly controlling dangerous drugs.

  3. January 30, 2023

    Opioid Victim Families Go To Trial Against Distributors In Ga.

    Nearly two dozen Georgians went to trial Monday against opioid distributors over claims the companies share blame for their family members' addictions, previewing some of the most personal stories told thus far in nationwide opioid litigation.

  4. January 17, 2023

    Mich. County Loses Challenge To $800M Opioid Payout Plan

    Michigan's first wave of funds from a national settlement with opioid distributors and manufacturers can start to flow to local governments after a federal court dismissed one county's challenge to how the funds were apportioned.

  5. January 03, 2023

    Health & Pharma Legal Clashes Didn't Take A Holiday Break

    While many Americans were bringing glad tidings and popping bubbly, attorneys spent the final week of 2022 bringing lawsuits, appeals and other court filings of eye-popping significance for health care providers and drug companies in cases involving the False Claims Act, the opioid crisis and purported price-fixing schemes.

  6. January 02, 2023

    Health Care & Life Sciences Litigation To Watch In 2023

    Before the New Year's Eve confetti has even been swept up, lawyers specializing in health care and life sciences already have enough litigation to keep them busy for much of 2023, which is kicking off with federal courts eyeing suits that carry sweeping significance for administrative law, the False Claims Act, drug approvals, the opioid crisis and abortion rights.

  7. December 13, 2022

    6th Circ. Rejects Challenge To Opioid MDL Fee Order

    A Sixth Circuit panel on Tuesday threw out challenges to a common benefit order in the sprawling opioid multidistrict litigation that sets aside a portion of future settlements to pay plaintiffs' counsel, saying the challengers don't have standing to undo the order through an appeal.

  8. December 12, 2022

    Walgreens And CVS Finalize $10.7B Opioid Fallout Deal

    Walgreens and CVS have nailed down the final details of their $10.7 billion deal with 18 states to end claims that they contributed to the national opioid crisis, according to statements Monday from multiple state attorneys general.

  9. December 01, 2022

    Top Opioid Target Kroger Inks $85M Deal, With $25M For Attys

    Supermarket giant Kroger is paying $85 million, including $25 million for plaintiff lawyers, to end opioid crisis lawsuits in New Mexico, according to settlement papers released Thursday, a relatively sizable sum that underscores the company's new status as a top target in nationwide opioid litigation. 

  10. November 23, 2022

    5 Years In, Opioid Attys Talk Historic Saga's Progress & Future

    Sprawling opioid litigation has unearthed pharmaceutical industry failures, altered attitudes about addiction and secured billions of dollars that are raising hopes that a bleak drug crisis in U.S. communities will eventually yield to brighter days, plaintiffs counsel told Law360 in a conversation about the five-year legal saga's progress — and its uncertain path forward.